Fig 1: MiR-1256 directly targets TCTN1. (A) The schematic diagram represents the presumptive binding site of miR-1256 and the 3′-UTR of the TCTN1. (B and C) Relative luciferase activity was detected in A549 and SK-MES-1 cells after co-transfected with TCTN1 3′-UTR (wild-type or mutant) and control or miR-1256 mimic, *P<0.05. (D) Quantitative analysis of TCTN1 expression in NSCLC and adjacent normal tissues (n=30, ***P<0.01). (E) TCTN1 protein expression in A549 cells and SK-MES-1 cells after transfected with control, miR-1256 mimic/inhibitor was detected by western blot analysis. (F and G) TCTN1 mRNA expression in A549 cells and SK-MES-1 cells after transfected with control, miR-1256 mimic/inhibitor was detected by qRT-PCR, *P<0.05; #P<0.05.
Fig 2: Knockdown of TCTN1 inhibits NSCLC cell proliferation and migration and TCTN1 reversed partial function of miR-1256. (A and B) The TCTN1 expression level in NSCLC cells after transfected with TCTN1 siRNA was detected by qRT-PCR and western blot analysis, *P<0.05, **P<0.01. (C and D) MTT and transwell assay, A549 cell proliferation and migration after knockdown of TCTN1, *P<0.05, **P<0.01. (E and F) Treatment with both miR-1256 inhibitor and siRNA TCTN1 reversed the promotion of A549 cell proliferative and migratory capacities compared with treatment with miR-1256 inhibitor alone, **P<0.01; #P<0.05; ##P<0.01. TCTN1, tectonic family member 1; NSCLC, non-small cell lung cancer; qRT-PCR, quantitative real-time PCR; MTT, methyl thiazolyl tetrazolium assay.
Supplier Page from Abcam for Anti-TCTN1 antibody